(P060) Evaluation of 4D-CT Acquisition Methods Designed to Reduce Artifacts

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Four-dimensional computed tomography (4D-CT) is used to account for respiratory motion in radiation treatment planning, but image artifacts resulting from the acquisition and postprocessing limit its accuracy.

Sarah J. Castillo, MS, Richard Castillo, PhD, Edward Castillo, PhD, Peter Balter, PhD, Tinsu Pan, PhD, Geoffrey Ibbott, PhD, Brian Hobbs, PhD, Thomas Guerrero, MD, PhD; UT Health Science Center; UT MD Anderson Cancer Center; Rice University

Introduction: Four-dimensional computed tomography (4D-CT) is used to account for respiratory motion in radiation treatment planning, but image artifacts resulting from the acquisition and postprocessing limit its accuracy.

Methods: We investigated the efficacy of three experimental 4D-CT acquisition methods to reduce artifacts in a prospective institutional review board (IRB)-approved study. Eighteen thoracic patients scheduled to undergo radiation therapy (RT) received standard clinical 4D-CT scans, followed by each of the alternative 4D-CT acquisitions: (1) data oversampling, (2) beam gating with breathing irregularities, and (3) rescanning the clinical acquisition acquired during irregular breathing. Relative values of a validated correlation-based artifact metric (CM) determined the best acquisition method per patient. Each 4D-CT scan was processed two ways: by clinical standard phase sorting and by extended phase sorting by optimization of the quantitative artifact metric (CM sorting).

Results: The CM-sorted oversampling acquisition achieved the lowest artifact presence among all acquisition and sorting combinations-a 38% reduction from the phase-sorted clinical acquisition. The CM-sorted oversampling and gating acquisitions both resulted in significant artifact reductions from the CM-sorted clinical (21% and 16%, respectively) and rescan (39% and 36%, respectively) acquisitions, with no significant difference between them. The gating acquisition achieved the highest artifact reduction among phase-sorted acquisitions but was not significant. The rescan acquisition resulted in a significantly higher artifact presence than all other acquisitions in each sorting technique.

Conclusions:  CM-sorted oversampling acquisition reduced artifact presence from the clinical phase-sorted acquisition to the largest degree, although both the gating and oversampling acquisitions can significantly reduce artifact presence in 4D-CT image sets when alternative quantitative correlation-based sorting is applied.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content